Cardiovascular revascularization medicine : including molecular interventions
-
Cardiovasc Revasc Med · Feb 2021
Meta AnalysisSafety and Efficacy of Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Given current evidence, the use of colchicine for the prevention of adverse cardiovascular events in patients with coronary artery disease (CAD) remains controversial. ⋯ In patients with CAD presenting with an acute coronary syndrome or stable angina, colchicine might offer no significant reduction in MACE and could potentially be harmful due to a significantly higher risk of GI-related adverse events.
-
Cardiovasc Revasc Med · Sep 2020
ReviewImplementation of Institutional Discharge Protocols and Transition of Care Following Acute Coronary Syndrome.
Despite improvements in acute care and survival following acute coronary syndrome (ACS) hospitalization, readmission remains common. In response, individual institutions have begun to develop their own protocols to reduce variability of care and readmission rates. ⋯ TABLE OF CONTENTS This review discusses approaches for developing and implementing institutional discharge protocols for continuity of care for patients with acute coronary syndrome. The discussion revolves around key components and objectives of a discharge protocol for facilitating successful transition of care.
-
Cardiovasc Revasc Med · Sep 2020
ReviewCost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients.
Transcatheter aortic valve intervention (TAVI) is known to be non-inferior to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients. This present systematic review was conducted to analyse the cost-effectiveness of TAVI in this patient population. ⋯ TAVI is likely to be a cost-effective alternative to SAVR in low-intermediate risk patients. More studies on low risk patients is needed.
-
Cardiovasc Revasc Med · Sep 2020
ReviewCost-effectiveness of transcatheter aortic valve intervention (TAVI) compared to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients.
Transcatheter aortic valve intervention (TAVI) is known to be non-inferior to surgical aortic valve replacement (SAVR) in low-intermediate surgical risk patients. This present systematic review was conducted to analyse the cost-effectiveness of TAVI in this patient population. ⋯ TAVI is likely to be a cost-effective alternative to SAVR in low-intermediate risk patients. More studies on low risk patients is needed.
-
Cardiovasc Revasc Med · Aug 2020
ReviewTreatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic.
The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. ⋯ While thrombolysis may seem like a good choice, many patients have a contraindication and could end up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy.